Prostaglandins and other lipid mediators in Alzheimer's disease

Prostaglandins and Other Lipid Mediators

Volumn 68-69, Issue , 2002, Pages 197-210

  Bazan, Nicolas G ^a   Colangelo, Vittorio ^a   Lukiw, Walter J ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease (AD); AP1; Arachidonic acid (AA) cycle; Brain membranes; Cytosolic phospholipase A2 (cPLA2); Isoprostane; Neuroinflammation, NF B; Platelet activating factor (PAF); Prostaglandin (PG); STAT1

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; ARACHIDONIC ACID; CYCLOOXYGENASE 2; FATTY ACID; ICOSANOID; LYSOPHOSPHOLIPID; NEUROFILAMENT PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PRESENILIN 1; PRESENILIN 2; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; SYNAPSIN; SYNAPTOBREVIN; THROMBOCYTE ACTIVATING FACTOR; CYCLOOXYGENASE 1; ISOENZYME; ISOPROSTANE DERIVATIVE; MEMBRANE PROTEIN; PHOSPHOLIPASE A; PROSTAGLANDIN; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; HUMAN; HYDROLYSIS; IMMUNOREACTIVITY; INFLAMMATION; NERVE DEGENERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BRAIN; DISEASE COURSE; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW; SECOND MESSENGER;

ALZHEIMER DISEASE; ARACHIDONIC ACID; BRAIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DISEASE PROGRESSION; ENZYME ACTIVATION; HUMANS; INFLAMMATION; ISOENZYMES; ISOPROSTANES; MEMBRANE PROTEINS; OXIDATIVE STRESS; PHOSPHOLIPASES A; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; SECOND MESSENGER SYSTEMS;

EID: 0036669582     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(02)00031-X     Document Type: Article

References (123)

1. Alzheimer A. Über eine eigenartige erkrankung der hirnrinde. Allg. Z. Psychiatry. 64:1907;146.
2. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2001;741.
3. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:1984;885.
4. Kang J., Lemaire H.G., Unterbeck A.et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 325:1987;733.
5. Masters C.L., Multhaup G., Simms G., Pottgiesser J., Martins R.N., Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4:1985;2757.
6. Tanzi R.E., McClatchey A.I., Lamperti E.D., Villa-Komaroff L., Gusella J.F., Neve R.L. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature. 331:1988;528.
7. Kitaguchi N., Takahashi Y., Tokushima Y., Shiojiri S., Ito H. Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity. Nature. 331:1988;530.
8. Ponte P., Gonzalez-DeWhitt P., Schilling J.et al. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature. 331:1988;525.
9. Roher A.E., Lowenson J.D., Clarke S.et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J. Biol. Chem. 268:1993;3072.
10. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13:1993;1676.
11. Busciglio J., Lorenzo A., Yankner B.A. Methodological variables in the assessment of beta-amyloid neurotoxicity. Neurobiol. Aging. 13:1992;609.
12. Mattson M.P., Tomaselli K.J., Rydel R.E. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res. 621:1993;35.
13. Lorenzo A., Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA. 91:1994;12243.
14. Busciglio J., Lorenzo A., Yeh J., Yankner B.A. Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 14:1995;879.
15. Howlett D.R., Jennings K.H., Lee D.C.et al. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration. 4:1995;23.
16. Hansen L.A., Crain B.J. Making the diagnosis of mixed and non-Alzheimer's dementias. Arch Pathol. Lab. Med. 119:1995;1023.
17. Bazan N.G. COX-2 as a multifunctional neuronal modulator. Nat. Med. 7:2001;414.
18. Poirier J. Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease. Mol. Diagn. 4:1999;335.
19. Greenfield JP, Gross RS, Gouras GK, Xu H. Cellular and molecular basis of beta-amyloid precursor protein metabolism. Front. Biosci. 2000;5:172.
20. Haass C., Baumeister R. The biological and pathological function of presenilin proteins. Eur. Arch. Psychiatry Clin. Neurosci. 49:1999;23.
21. St George-Hyslop P.H. Molecular genetics of Alzheimer disease. Semin. Neurol. 19:1999;371.
22. Strittmatter W.J., Saunders A.M., Schmechel D.et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;1977.
23. Roses A.D. Apolipoprotein E and Alzheimer's disease the tip of the susceptibility iceberg. Ann. NY Acad. Sci. 855:1998;738.
24. Okuizumi K. The role of apolipoprotein E in the pathogenesis of Alzheimer disease. Nippon Rinsho. 57:1999;2673.
25. Sherrington R., Rogaev E.I., Liang Y.et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 375:1995;754.
26. Levy-Lahad E., Poorkaj P., Wang K. Genomic structure and expression of STM2, the chromosome 1 familial Alzheimer disease gene. Genomics. 34:1996;198.
27. Rogaev E.I., Sherrington R., Wu C.et al. Analysis of the 5′ sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease. Genomics. 40:1999;415.
28. Rogaev E.I. Genetic factors and a polygenic Mof Alzheimer's disease. Genetika. 35:1999;1558.
29. Lee M.K., Cleveland D.W. Neuronal intermediate filaments. Curr. Opin. Cell Biol. 6:1994;34.
30. McLachlan D.R., Lukiw W.J., Wong L., Bergeron C., Bech-Hansen N.T. Selective messenger RNA reduction in Alzheimer's disease. Mol. Brain Res. 3:1988;255.
31. Lukiw W.J., Wong L., McLachlan D.R.C. Cytoskeletal messenger RNA stability in human neocortex: studies in normal aging and in Alzheimer's disease. Int. J. Neurosci. 55:1990;81.
32. Julien J.P., Mushynski W.E. Neurofilaments in health and disease. Prog. Nucleic Acid Res. Mol. Biol. 61:1996;1.
33. Julien J.P. Neurofilament functions in health and disease. Curr. Opin. Neurobiol. 9:1999;554.
34. Trimble W.S., Cowan D.M., Scheller R.H. VAMP-1: a synaptic vesicle-associated integral membrane protein. Proc. Natl. Acad. Sci. USA. 859:1988;4538.
35. Elferink L.A., Trimble W.S., Scheller K. Two vesicle-associated membrane protein genes are differentially expressed in the rat central nervous system. J. Biol. Chem. 264:1989;11061.
36. Ralston E., Beushausen S., Ploug T. Expression of the ssynaptic vesicle proteins vamps/synaptobrevins 1 and 2 in non-neural tissues. J. Biol. Chem. 269:1994;15403.
37. (2+) - but not for GTP gamma S-induced insulin secretion. EMBO J. 14:1995;2723.
38. Lukiw W.J., Rogaev E.I., Bazan N.G. Synaptic and cytoskeletal RNA message levels in sporadic Alzheimer neocortex. Alzheimer's Res. 2:1996;221.
39. Ferrer I., Rivera R., Blanco R., Marti E. Expression of proteins linked to exocytosis and neurotransmission in patients with Creutzfeldt-Jakob disease. Neurobiol. Dis. 6:1999;92.
40. Leube R.E., Kaiser P., Seiter Zimbelmann R.et al. Synaptophysin: molecular organization and mRNA expression as determined from cloned cDNA. EMBO J. 6:1987;3261.
41. Elferink L.A., Scheller R.H. Synaptic vesicle proteins and regulated exocytosis. Prog. Brain Res. 105:1995;79.
42. Heffernan J.M., Eastwood S.L., Nagy Z., Sanders M.W., McDonald B., Harrison P.J. Temporal cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively correlated with the severity of dementia. Exp. Neurol. 150:1998;235.
43. Chow N., Cox C., Callahan L.M., Weimer J.M., Guo L., Coleman P.D. Expression profiles of multiple genes in single neurons of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 95:1998;9620.
44. Callahan L.M., Vaules W.A., Coleman P.D. Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 58:1999;275.
45. Sudhof T.C. The structure of the human synapsin I gene and protein. J. Biol. Chem. 265:1990;7849.
46. Melloni R.H. Jr., Hemmendinger L.M., Hamos J.E., DeGennaro L.J. Synapsin I gene expression in the adult rat brain with comparative analysis of mRNA and protein in the hippocampus. J. Comp. Neurol. 327:1993;507.
47. Ferreira A., Han H.Q., Greengard P., Kosik K.S. Suppression of synapsin II inhibits the formation and maintenance of synapses in hippocampal culture. Proc. Natl. Acad. Sci. 92:1995;9225.
48. Chin L.S., Li L., Ferreira A., Kosik K.S., Greengard P. Impairment of axonal development and of synaptogenesis in hippocampal neurons of synapsin I-deficient mice. Proc. Natl. Acad. Sci. USA. 92:1995;9230.
49. Vane J.R., Botting R.M. Mechanism of action of anti-inflammatory drugs. Scand. J. Rheumatol. Suppl. 102:1996;9.
50. Lukiw W.J., Bazan N.G. COX-2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J. Neurosci. Res. 15:1997;50.
51. Pasinetti G.M., Aisen P.S. COX-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 87:1998;319.
52. Kitamura Y., Shimohama S., Koik e H.et al. Increased expression of COXs and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 254:1999;582.
53. Adelizzi R.A. COX-1 and COX-2 in health and disease. J. Am. Osteopath. Assoc. 99:1999;S7.
54. 2 and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. J. Biol. Chem. 271:1996;32722.
55. 2. Crit. Rev. Immunol. 17:1997;225.
56. Lennartz M.R. Phospholipases and phagocytosis: the role of phospholipid-derived second messengers in phagocytosis. Int. J. Biochem. Cell Biol. 31:1999;415.
57. 2 inhibitors in endotoxic shock. Injury. 30:1999;9.
58. 2+ oscillations in pancreatic acinar cells. Pancreas. 20:2000;77.
59. Shimizu T., Wolfe L.S. Arachidonic acid cascade and signal transduction. J. Neurochem. 55:1990;1.
60. Smith WL, Borgeat P, Fitzpatrick FA. In: Vance DE, Vance J, editors. Biochemistry, Lipoproteins, and Membranes. New York: Elsevier, 1991. p. 297.
61. Bazan N.G., Rodriguez de Turco E.B., Allan G. Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. J. Neurotrauma. 12:1995;791.
62. Bazan N.G. The neuromessenger platelet-activating factor in plasticity and neurodegeneration. Prog. Brain Res. 118:1998;281.
63. 2 inhibitors, PAF acetylhydrolases, PAF receptor antagonists and free radical scavengers PGs leukot. Essent. Fatty Acids. 61:1999;65.
64. McGeer P.L., McGeer E.G. Inflammation of the brain in Alzheimer's disease: implications for therapy. J. Leukoc. Biol. 65:1999;409.
65. Breitner J.C., Gau B.A., Welsh K.A.et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 44:1994;227.
66. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:1996;425.
67. Rogers J., Kirby L.C., Hempelman S.R.et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609.
68. Lukiw W.J., Carver L.A., LeBlanc H.J., Bazan N.G. Analysis of 1184 gene transcript levels in Alzheimer CA1 hippocampus: synaptic signaling and transcription factor deficits and upregulation of proinlammatory pathways. Alzheimer's Reports. 3:2000;161.
69. Kraemer S.A., Meade E.A., DeWitt D.L. PG Endoperoxide synthase gene structure: identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch. Biochem. Biophys. 293:1992;391.
70. Fletcher B.S., Kujubu D.A., Perrin D.M., Herschman H.R. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional PG G/H synthase. J. Biol. Chem. 267:1992;4338.
71. Smith W.L., De Witt D.L. Biochemistry of PG endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin. Nephrol. 15:1995;179.
72. Diaz-Cazorla M., Perez-Sala D., Ros J., Jimenez W., Fresno M., Lamas S. Regulation of COX-2 expression in human mesangial cells - transcriptional inhibition by IL-13. Eur. J. Biochem. 260:1999;268.
73. Hayashi Y., Kobayashi M., Kuwata H.et al. Interferon-gamma and interleukin 4 inhibit interleukin 1 beta-induced delayed PG E(2) generation through suppression of COX-2 expression in human fibroblasts. Cytokine. 12:2000;603.
74. 2. Lab. Invest. 75:1996;529.
75. O'Banion M.K. COX-2: molecular biology, pharmacology, and neurobiology. Crit. Rev. Neurobiol. 13:1999;45.
76. Onoe Y., Miyaura C., Kaminakayashiki T. IL-13 and IL-4 inhibit bone resorption by suppressing COX-2-dependent PG synthesis in osteoblasts. J. Immunol. 156:1996;758.
77. Smith W.L., Garavito R.M., DeWitt D.L. PG endoperoxide H synthases (COXs)-1 and -2. J. Biol. Chem. 271:1996;33157.
78. Vane J.R., Bakhle Y.S., Botting R.M. COXs 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38:1998;97.
79. Lukiw W.J., Bazan N.G. Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochem. Res. 25:2000;1173.
80. Pasinetti G.M. COX and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J. Neurosci. Res. 54:1998;1.
81. Pasinetti G.M. COX and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia. Arch. Gerontol. Geriatr. 33:2001;13.
82. Yamagata K., Andreasson K.I., Kaufmann W.E.et al. Expression of a mitogen-inducible COX in brain neurons. Neuron. 11:1993;371.
83. Breder C.D. COX systems in the mammalian brain. Ann. NY Acad. Sci. 15:1997;813.
84. Kaufmann W.E., Andreasson K.I., Isakson P.C.et al. COX and the central nervous system. Prostaglandins. 54:1997;601.
85. Kaufmann W.E., Worley P.F., Pegg J., Bremer M., Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. USA. 93:1996;2317.
86. Breitner J.C. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu. Rev. Med. 47:1996;401.
87. Rich J.B., Rasmusson D.X., Folstein M.F., Carson K.A., Kawas C., Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 45:1995;51.
88. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626.
89. Deininger M.H., Weller M., Streffer J., Mittelbronn M., Meyermann R. Patterns of COX-1 and-2 expression in human gliomas in vivo. Acta Neuropathol. (Berl.). 98:1999;240.
90. Hoozemans J.J., Rozemuller A.J., Janssen I., De Groot C.J., Veerhuis R., Eikelenboom P. COX expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. (Berl.). 101:2001;2.
91. Yermakova A.V., Rollins J., Callahan L.M., Rogers J., O'Banion M.K. COX-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J. Neuropathol. Exp. Neurol. 58:1999;1135.
92. Mackenzie I.R., Munoz D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 50:1998;986.
93. Degi R., Bari F., Beasley T.C.et al. Regional distribution of PG H synthase-2 and neuronal nitric oxide synthase in piglet brain. Pediatr. Res. 43:1998;683.
94. Chang J.W., Coleman P.D., O'Banion M.K. PG G/H synthase-2 (COX-2) mRNA expression is decreased in Alzheimer's disease. Neurobiol. Aging. 17:1996;801.
95. O'Banion M.K., Miller J.C., Chang J.W., Kaplan M.D., Coleman P.D. Interleukin-1 beta induces PG G/H synthase-2 (COX-2) in primary murine astrocyte cultures. J. Neurochem. 66:1996;2532.
96. Nam M.J., Thore C., Busija D. Effects of protein kinase c activation on PG production and COX mRNA levels in ovine astroglia. Prostglandins. 51:1996;203.
97. Luo J., Lang J.A., Miller M.W. Transforming growth factor beta 1 regulates the expression of COX in cultured cortical astrocytes and neurons. J. Neurochem. 71:1998;526.
98. Mollace V., Colasanti M., Muscoli C.et al. The effect of nitric oxide on cytokine-induced release of PGE2 by human cultured astroglial cells. Br. J. Pharmacol. 124:1998;742.
99. Hoozemans J.J., Veerhuis R., Janssen I., Rozemuller A.J., Eikelenboom P. Interleukin-1 beta induced COX 2 expression and PG E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. Exp. Gerontol. 36:2001;559.
100. Ho L., Pieroni C., Winger D., Purohit D.P., Aisen P.S., Pasinetti G.M. Regional distribution of COX-2 in the hippocampal formation in Alzheimer's disease. J. Neurosci. Res. 57:1999;295.
101. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Distribution of COX-1 and COX-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 830:1999;226.
102. Luterman J.D., Haroutunian V., Yemul S.et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease Dementia. Arch. Neurol. 57:2000;1153.
103. Griffin W.S., Sheng J.G., Roberts G.W., Mrak R.E. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54:1995;276.
104. Huell M., Strauss S., Volk B., Berger M., Bauer J. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol. (Berl.). 89:1995;544.
105. Strauss S., Bauer J., Ganter U., Jonas U., Berger M., Volk B. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab. Invest. 66:1992;223.
106. Dash P.K., Moore A.N. Enhanced processing of APP Induced by IL-1 beta can be reduced by indomethacin and nordihydroguaiaretic acid. Biochem. Biophys. Res. Commun. 208:1995;542.
107. Fiebich B.L., Hull M., Lieb K., Gyufko K., Berger M., Bauer J. Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. J. Neurochem. 68:1997;704.
108. Oka A., Takashima S. Induction of cyclooxygenase 2 in brains of patients with down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport. 8:1997;1161.
109. Kadoyama K., Takahashi Y., Higashida H., Tanabe T., Yoshimoto T. COX-2 stimulates production of amyloid beta-peptide in neuroblastoma X glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun. 281:2001;483.
110. Adams J., Collaço-Moraes Y., de Belleroche J. COX-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J. Neurochem. 66:1996;6.
111. Olney J.W., Wozniak D.F., Farber N.B. Excitotoxic neurodegeneration in Alzheimer disease. new hypothesis and new therapeutic strategies. Arch. Neurol. 54:1997;1234.
112. Kawaguchi K., Huerbin M., Simon R.P. Lesioning of deep prepiriform cortex protects against ischemic neuronal necrosis by attenuating extracellular glutamate concentrations. J. Neurochem. 69:1997;412.
113. Kelley K.A., Ho L., Winger D.et al. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal COX-2. Am. J. Pathol. 155:1999;995.
114. Butterfield D.A., Howard B.J., LaFontaine M.A. Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease. Curr. Med. Chem. 8:2001;815.
115. Hsu C.Y., Liu T.H., Xu J.et al. Arachidonic acid and its metabolites in cerebral ischemia. Ann. NY Acad. Sci. 559:1989;282.
116. Landino L.M., Crews B.C., Timmons M.D., Morrow J.D., Marnett L.J. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc. Natl. Acad. Sci. USA. 93:1996;15069.
117. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17:1997;2653.
118. Greco A., Minghetti L., Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem. Res. 25:2000;1357.
119. Pratico D., Uryu K., Leight S., Trojanoswki J.Q., Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21:2001;4183.
120. Terry R.D., Masliah E., Salmon D.P. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30:1991;572.
121. Renvoize E.B., Mindham R.H., Stewart M., McDonald R., Wallace R.D. Identical twins discordant for presenile dementia of the Alzheimer type. Br. J. Psychiatry. 149:1986;509.
122. Nee L.E., Eldridge R., Sunderland T. Dementia of the Alzheimer type: clinical and familial study of 22 twin pairs. Neurology. 37:1987;359.
123. Rapoport S.I., Pettigrew K.D., Schapiro M.B. Discordance and concordance of dementia of the Alzheimer type (DAT) in monozygotic twins indicate heritable and sporadic forms of Alzheimer's disease. Neurology. 41:1991;1549.